Korean Drug Co., Ltd. (KOSDAQ:014570)
South Korea
· Delayed Price · Currency is KRW 4,575.00
+110.00 (2.46%)
Last updated: Apr 1, 2025
Korean Drug Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Operating Revenue | 73,001 | 81,375 | 79,984 | 74,466 | 66,789 | Upgrade
|
| Other Revenue | - | -0 | -0 | -0 | - | Upgrade
|
| Revenue | 73,001 | 81,375 | 79,984 | 74,466 | 66,789 | Upgrade
|
| Revenue Growth (YoY) | -10.29% | 1.74% | 7.41% | 11.49% | 20.28% | Upgrade
|
| Cost of Revenue | 38,600 | 44,025 | 45,467 | 43,400 | 38,100 | Upgrade
|
| Gross Profit | 34,401 | 37,350 | 34,517 | 31,065 | 28,689 | Upgrade
|
| Selling, General & Admin | 24,137 | 18,136 | 19,111 | 18,529 | 16,530 | Upgrade
|
| Other Operating Expenses | 677.64 | 724.2 | 662 | 745.93 | 662.9 | Upgrade
|
| Operating Expenses | 30,296 | 30,630 | 20,188 | 19,799 | 17,650 | Upgrade
|
| Operating Income | 4,105 | 6,720 | 14,329 | 11,266 | 11,039 | Upgrade
|
| Interest Expense | -4.24 | -3.02 | -2.1 | -1.53 | -3.13 | Upgrade
|
| Interest & Investment Income | 594.69 | 1,213 | 621.01 | 133.66 | 166.91 | Upgrade
|
| Earnings From Equity Investments | - | - | - | - | -576.86 | Upgrade
|
| Currency Exchange Gain (Loss) | 3.48 | 1.55 | 84.73 | 98.22 | -74.65 | Upgrade
|
| Other Non Operating Income (Expenses) | 218.47 | 205.88 | 32.88 | 182.37 | 227.81 | Upgrade
|
| EBT Excluding Unusual Items | 4,917 | 8,137 | 15,066 | 11,679 | 10,779 | Upgrade
|
| Gain (Loss) on Sale of Investments | 72.9 | 132.87 | -383.6 | -359.46 | -1,534 | Upgrade
|
| Gain (Loss) on Sale of Assets | 3.56 | -4.78 | 2.81 | 1.13 | -5.28 | Upgrade
|
| Pretax Income | 4,994 | 8,265 | 14,685 | 11,321 | 9,240 | Upgrade
|
| Income Tax Expense | 1,998 | 13,182 | 2,876 | 2,278 | 1,880 | Upgrade
|
| Net Income | 2,995 | -4,917 | 11,809 | 9,042 | 7,360 | Upgrade
|
| Net Income to Common | 2,995 | -4,917 | 11,809 | 9,042 | 7,360 | Upgrade
|
| Net Income Growth | - | - | 30.59% | 22.86% | 88.94% | Upgrade
|
| Shares Outstanding (Basic) | 11 | 11 | 11 | 11 | 11 | Upgrade
|
| Shares Outstanding (Diluted) | 11 | 11 | 11 | 11 | 11 | Upgrade
|
| Shares Change (YoY) | -0.08% | -0.01% | -1.26% | 0.46% | -0.37% | Upgrade
|
| EPS (Basic) | 278.00 | -456.00 | 1095.09 | 828.00 | 677.00 | Upgrade
|
| EPS (Diluted) | 278.00 | -456.00 | 1095.09 | 828.00 | 677.00 | Upgrade
|
| EPS Growth | - | - | 32.26% | 22.30% | 89.64% | Upgrade
|
| Free Cash Flow | 3,842 | -2,119 | -180.15 | 7,660 | 11,592 | Upgrade
|
| Free Cash Flow Per Share | 356.60 | -196.54 | -16.71 | 701.43 | 1066.29 | Upgrade
|
| Gross Margin | 47.12% | 45.90% | 43.16% | 41.72% | 42.95% | Upgrade
|
| Operating Margin | 5.62% | 8.26% | 17.91% | 15.13% | 16.53% | Upgrade
|
| Profit Margin | 4.10% | -6.04% | 14.76% | 12.14% | 11.02% | Upgrade
|
| Free Cash Flow Margin | 5.26% | -2.60% | -0.22% | 10.29% | 17.36% | Upgrade
|
| EBITDA | 6,174 | 8,469 | 15,712 | 12,736 | 12,394 | Upgrade
|
| EBITDA Margin | 8.46% | 10.41% | 19.64% | 17.10% | 18.56% | Upgrade
|
| D&A For EBITDA | 2,069 | 1,749 | 1,383 | 1,470 | 1,355 | Upgrade
|
| EBIT | 4,105 | 6,720 | 14,329 | 11,266 | 11,039 | Upgrade
|
| EBIT Margin | 5.62% | 8.26% | 17.91% | 15.13% | 16.53% | Upgrade
|
| Effective Tax Rate | 40.02% | 159.49% | 19.58% | 20.13% | 20.35% | Upgrade
|
| Advertising Expenses | 900.89 | 920.23 | 1,014 | 1,082 | 1,231 | Upgrade
|
Updated Mar 1, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.